Optometrists in Warrenton, OR Accepting Medicare
6 Optometrists found. Showing 1 - 6
 Neal James Garhofer, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 695 S Highway 101, Warrenton, OR 97146 Phone: 503-861-9829 Fax: 503-861-9830 |
 Thuy Nguyen Od Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1804 Se Ensign Ln, Warrenton, OR 97146 Phone: 503-338-4114 |
Scott Robert Kurita, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1804 Se Ensign Ln, Warrenton, OR 97146 Phone: 503-338-4114 Fax: 503-338-4115 |
Dr. Claude N Stevens Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1804 Se Ensign Ln, Optometry, Warrenton, OR 97146 Phone: 503-338-4101 |
Dr. Robert Page Hamilton, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1804 Se Ensign Ln, Optometry Department, Warrenton, OR 97146 Phone: 503-338-4114 Fax: 503-338-4113 |
Kurita Eye Care Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1804 Se Ensign Ln, Warrenton, OR 97146 Phone: 503-338-4114 Fax: 503-338-4115 |
News Archive
New communication training could help nephrology fellows to discuss serious news with patients
Kidney specialists, or nephrologists, care for a medically complex population and frequently must discuss serious news with patients: giving a diagnosis of kidney disease, explaining the risks and benefits of treatments, and defining care goals at the end of life. Yet nephrologists do not routinely receive formal education on how to engage in these types of conversations.
Ceregene announces new data from CERE-120 clinical trial on Parkinson's
Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.
Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).
New study finds dramatic increase in young athletes undergoing Tommy John surgery
A new study found a dramatic increase in the number of adolescents undergoing "Tommy John" surgery to repair a pitching-related elbow injury in recent years, outstripping growth among major league pitchers.
› Verified 9 days ago
Optometrists
Chiropractors
Audiologists
Physical Therapists
Occupational Therapists